vs
Side-by-side financial comparison of Ares Commercial Real Estate Corp (ACRE) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Ares Commercial Real Estate Corp is the larger business by last-quarter revenue ($13.2M vs $9.1M, roughly 1.4× Protalix BioTherapeutics, Inc.). Ares Commercial Real Estate Corp runs the higher net margin — -29.2% vs -60.3%, a 31.1% gap on every dollar of revenue. On growth, Ares Commercial Real Estate Corp posted the faster year-over-year revenue change (-24.5% vs -49.9%). Over the past eight quarters, Protalix BioTherapeutics, Inc.'s revenue compounded faster (-6.7% CAGR vs -15.9%).
Ares Commercial Real Estate Corp is a specialty finance company focused on the commercial real estate sector. It offers a full suite of customized financing solutions including senior mortgage loans, subordinated debt and preferred equity, primarily serving middle-market commercial property owners and operators across the United States.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
ACRE vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.2M | $9.1M |
| Net Profit | $-3.9M | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | -29.2% | -51.1% |
| Net Margin | -29.2% | -60.3% |
| Revenue YoY | -24.5% | -49.9% |
| Net Profit YoY | 63.8% | -184.8% |
| EPS (diluted) | — | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.2M | $9.1M | ||
| Q3 25 | $14.1M | $17.9M | ||
| Q2 25 | $12.6M | $15.7M | ||
| Q1 25 | $14.9M | $10.1M | ||
| Q4 24 | $17.5M | $18.2M | ||
| Q3 24 | $16.7M | $18.0M | ||
| Q2 24 | $16.8M | $13.5M | ||
| Q1 24 | $18.7M | — |
| Q4 25 | $-3.9M | $-5.5M | ||
| Q3 25 | $4.7M | $2.4M | ||
| Q2 25 | $-11.0M | $164.0K | ||
| Q1 25 | $9.3M | $-3.6M | ||
| Q4 24 | $-10.7M | $6.5M | ||
| Q3 24 | $-5.9M | $3.2M | ||
| Q2 24 | $-6.1M | $-2.2M | ||
| Q1 24 | $-12.3M | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
| Q4 25 | -29.2% | -51.1% | ||
| Q3 25 | 33.0% | 11.9% | ||
| Q2 25 | -87.8% | 7.5% | ||
| Q1 25 | 64.4% | -41.0% | ||
| Q4 24 | -61.0% | 39.6% | ||
| Q3 24 | -35.3% | 22.2% | ||
| Q2 24 | -36.5% | -18.0% | ||
| Q1 24 | -65.9% | — |
| Q4 25 | -29.2% | -60.3% | ||
| Q3 25 | 33.0% | 13.2% | ||
| Q2 25 | -87.8% | 1.0% | ||
| Q1 25 | 62.5% | -35.8% | ||
| Q4 24 | -60.9% | 35.6% | ||
| Q3 24 | -35.3% | 18.0% | ||
| Q2 24 | -36.5% | -16.4% | ||
| Q1 24 | -65.9% | — |
| Q4 25 | — | $-0.06 | ||
| Q3 25 | — | $0.03 | ||
| Q2 25 | — | $0.00 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $0.03 | ||
| Q2 24 | — | $-0.03 | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $29.3M | $14.7M |
| Total DebtLower is stronger | $948.2M | — |
| Stockholders' EquityBook value | $509.6M | $48.2M |
| Total Assets | $1.6B | $82.3M |
| Debt / EquityLower = less leverage | 1.86× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $29.3M | $14.7M | ||
| Q3 25 | $84.9M | $13.6M | ||
| Q2 25 | $90.0M | $17.9M | ||
| Q1 25 | $125.5M | $19.5M | ||
| Q4 24 | $63.8M | $19.8M | ||
| Q3 24 | $68.9M | $27.4M | ||
| Q2 24 | $70.6M | $23.4M | ||
| Q1 24 | $99.5M | — |
| Q4 25 | $948.2M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $718.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $509.6M | $48.2M | ||
| Q3 25 | $521.0M | $52.9M | ||
| Q2 25 | $523.7M | $49.9M | ||
| Q1 25 | $542.1M | $45.2M | ||
| Q4 24 | $540.1M | $43.2M | ||
| Q3 24 | $563.8M | $32.4M | ||
| Q2 24 | $582.3M | $28.6M | ||
| Q1 24 | $601.1M | — |
| Q4 25 | $1.6B | $82.3M | ||
| Q3 25 | $1.4B | $82.3M | ||
| Q2 25 | $1.4B | $78.5M | ||
| Q1 25 | $1.5B | $73.9M | ||
| Q4 24 | $1.8B | $73.4M | ||
| Q3 24 | $1.9B | $61.6M | ||
| Q2 24 | $2.1B | $91.5M | ||
| Q1 24 | $2.1B | — |
| Q4 25 | 1.86× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.33× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $21.4M | $2.0M |
| Free Cash FlowOCF − Capex | — | $1.6M |
| FCF MarginFCF / Revenue | — | 17.8% |
| Capex IntensityCapex / Revenue | — | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $21.4M | $2.0M | ||
| Q3 25 | $3.8M | $-3.7M | ||
| Q2 25 | $4.9M | $-5.2M | ||
| Q1 25 | $8.0M | $-5.1M | ||
| Q4 24 | $35.5M | $4.0M | ||
| Q3 24 | $8.4M | $4.1M | ||
| Q2 24 | $8.7M | $-3.6M | ||
| Q1 24 | $11.4M | — |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | — | — |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.82× | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | 0.86× | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACRE
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
